查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1624386

全球流感诊断市场规模（按产品、最终用户、测试类型、地区、范围和预测）

Global Influenza Diagnostics Market Size By Product (test kits and reagents, instruments), By End User (diagnostics laboratories, hospitals & clinic), By Test Type (traditional test, molecular diagnostic assay), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

流感诊断市场规模及预测

流感诊断市场规模预计在 2024 年达到 8.4 亿美元，到 2031 年将达到 15.6 亿美元，2024 年至 2031 年的复合年增长率为 9.00%。流行性感冒（Influenza），俗称流感，是由流感病毒引起的传染病。有多种常规和分子诊断技术用于识别和诊断流感。逆转录聚合酶链反应和即时分子测试可以检测流感遗传物质。流感的快速诊断检测方法不断改进，快速的结果和样本采集的便利性使该方法可用于诊断。流感疫情的不断加剧、人们对使用特定诊断测试进行早期发现的认识不断提高以及重点从集中实验室转移到分散的即时检测是推动全球流感诊断市场成长的一些因素。

此外，由于慢性病盛行率不断上升、老龄人口不断增长、政府加强流感监测措施以及技术先进的流感诊断测试的发展，预计流感诊断的需求将会增加。

预计新的技术先进的流感诊断测试，包括即时诊断技术与流感检测的整合，将促进老年族群的监测过程。此外，预计即时诊断技术将增加亚太地区医疗保健有限的农村地区的流感检测。

然而，测试和设备开发的成本可能会成为市场发展的障碍。原材料供应和可及性的限制增加了产品的总成本。高昂的製造成本负担以更高的价格转嫁给最终用户。

全球流感诊断市场动态

主要市场推动因素

流感负担加重：

全球季节性流感流行导致大量发病率、住院率和死亡率，凸显了对快速且准确的诊断技术的必要性。这些工具对于做出治疗决策和实施有效的管理措施至关重要。

增强医疗保健意识：

随着大众对流感及其影响的认识不断提高，对快速、易于使用的诊断测试的需求也日益增长。这一发展反映了人们对医疗保健的积极态度，人们寻求易于获得的诊断解决方案。

技术进步：

快速分子检测、即时诊断和多重检测等新技术正在改变流感诊断。这些进步透过提高速度、准确性以及同时识别多种流感病毒株的能力提高了诊断能力。

强调早期发现与治疗：

早发现、早期治疗，对于流感的早期治疗和预防併发症至关重要。快速诊断测试可以实现更早的抗病毒药物治疗，改善患者的治疗效果并降低医疗成本。

老年人口不断增加

随着世界人口老化，老年人特别容易受到流感相关疾病的影响。这种人口结构的变化凸显了适合老年人需求的可靠、易于取得的诊断测试的重要性。

生物威胁防范：

流感病毒有可能引发大流行，因此快速且准确的诊断技术对于生物威胁的防范和应对活动至关重要。有效的诊断对于控制疫情和减少损害至关重要。

政府措施和报销政策：

一些政府已经启动公共卫生计划来促进流感疫苗接种和诊断。此外，流感诊断测试的优惠支付条款在提高可及性和鼓励广泛使用这些关键设备方面发挥关键作用。

主要课题

测试敏感性和特异性各不相同：

测试表现的变化，尤其是快速测试，可能导致流感与其他呼吸道感染的区分不准确，从而导致误诊和不适当的治疗建议。

高级测试成本昂贵：

分子检测等先进技术虽然准确性更高，但成本也更高，限制了人们的使用，尤其是在医疗预算有限的资源贫乏地区。

缺乏标准化：

多种具有不同性能特征的流感诊断测试的流行使测试结果的解释和比较变得复杂，给医疗保健专业人员带来了不确定性，并妨碍了有效的患者治疗决策。

偏远地区可用性有限：

偏远和低收入地区无法获得先进的诊断检测可能会延误诊断和治疗，尤其是对于那些难以获得具有先进检测能力的医疗机构的社区。明显。

熟练劳动力短缺：

一些较新的流感诊断测试需要特殊的训练和技能才能正确操作和解释。即使可以进行此类测试，由于某些地方缺乏合格的人员，因此无法有效地使用。

医疗费用问题：

流感诊断的报销规定薄弱可能会阻碍医疗保健提供者采用新技术，从而限制整体市场的成长和获得改进的测试的机会。

假阳性和假阴性：

儘管有所改进，但一些测试仍然会产生假阳性和假阴性结果，这会导致治疗浪费、资源浪费、患者焦虑以及测试方法的有效性和成本效益降低。

不断进化的病毒株：

流感病毒会不断变化，诊断方法需要不断更新和修改才能保持成功。新病毒株的引入可能会增加诊断製造商维持准确可靠诊断系统的费用和障碍。

主要趋势

采用快速诊断测试：

快速流感诊断测试（RIDT）因其方便、快速、易用而越来越受欢迎，能够在护理点快速做出治疗决策。

多重检测的出现：

多重检测正变得越来越流行，因为它们可以在一次测试中检测出许多呼吸道感染，例如流感病毒和呼吸道合胞病毒，从而提高效率并消除了多次测试的需要。

重点在于即时诊断检测（POCT）：

业界正转向开髮用于流感诊断的即时诊断（POCT）检测解决方案，为诊所、药房和家庭等各种场所提供便携、易于使用的选项。

与远距医疗平台整合：

流感诊断测试正在迅速连接到远距医疗平台，以实现远距诊断和咨询，从而改善人们获得医疗保健的机会，尤其是在弱势群体中。

分子诊断的技术进步：

随着技术的进步，用于流感诊断的更敏感和更具体的分子检测方法正在被开发出来，从而可以区分不同的流感病毒株，并促进有针对性的治疗策略和疫苗开发。

人工智慧整合：

人工智慧 (AI) 演算法正在整合到流感诊断中，诊断测试的数据分析有助于提高准确性、识别新菌株并预测疫情。

强调在家测试：

COVID-19 疫情增加了家庭诊断测试的需求，并且由于易于使用的自测剂盒的进步，预计流感诊断也将出现类似的趋势。

目录

第 1 章 简介

  • 市场定义
  • 市场细分
  • 调查日程
  • 先决条件
  • 限制

第2章 研究方法

  • 数据挖掘
  • 二次调查
  • 初步调查
  • 专家建议
  • 品质检查
  • 最终审查
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 数据源

第3章 执行摘要

  • 全球流感诊断市场概览
  • 流感诊断领域：绝对的获利机会
  • 全球流感诊断市场各区域吸引力
  • 全球流感诊断市场产品吸引力
  • 全球流感诊断市场对最终用户的吸引力
  • 全球流感诊断市场吸引力（按测试类型划分）
  • 全球流感诊断市场区域分析
  • 全球流感诊断市场（按产品）
  • 全球流感诊断市场（按最终用户划分）
  • 全球流感诊断市场（按检测类型）
  • 未来市场机会
  • 世界市场区隔

第4章市场展望

  • 全球流感诊断市场的变化
  • 全球流感诊断市场展望
  • 市场驱动力
    • 流感诊断技术研究的成长
    • 流感疫情加剧
  • 阻碍因素
    • 未经训练的专家
    • 严格的 FDA 规定
  • 可能性
    • 基因组学和蛋白质组学技术的进展
    • 增加研发活动
  • COVID-19 对全球流感诊断市场的影响
  • 波特五力分析
    • 买方议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的竞争
  • 价值链分析
  • 宏观经济分析

第 5 章最终用户市场

  • 概述
  • 诊断实验室
  • 医院/诊所
  • 其他

第6章 按产品划分的市场

  • 概述
  • 检测试剂和试剂
  • 检验设备
  • 其他

第 7 章 按测试类型划分的市场

  • 概述
  • 常规诊断测试
    • 快速流感诊断检测 (RIDT)
    • 病毒培养
    • 直接萤光抗体（DFA）检测
    • 血清学检测
  • 分子诊断测试
    • RT-PCR 方法
    • 基于核酸序列的扩增 (NASBA) 测试
    • 环介导等温扩增 (LAMP)
    • 简单扩增方法（samba）
    • 其他分子诊断检测

第8章区域市场

  • 概述
  • 北美
    • 北美市场快照
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲市场快照
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 亚太市场概况
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 拉丁美洲
    • 拉丁美洲市场概况
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • 中东/非洲市场概况
    • 阿拉伯联合酋长国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲

第9章 竞争格局

  • 概述
  • 竞争情景
  • 各公司市场排名分析
  • 区域足迹
  • 按行业划分的企业足迹
  • 王牌矩阵
    • 积极的
    • 前线
    • 新兴市场
    • 创新者

第10章 公司简介

  • ABBOTT LABORATORIES
  • THERMO FISHER SCIENTIFIC INC.
  • DANAHER CORPORATION
  • SIEMENS HEALTHINEERS AG
  • HOFFMANN-LA ROCHE AG
  • BECTON, DICKINSON, AND COMPANY
  • DIASORIN & LUMINEX CORPORATION
  • QUIDEL CORPORATION
  • CORIS BIOCONCEPT
  • ANALYTIK JENA AG（ENDRESS+HAUSER AG）
  • MERIDIAN BIOSCIENCE
  • SA SCIENTIFIC, LTD
  • SEKISUI DIAGNOSTIC
  • HOLOGIC INC.
  • 3M
  • BIOMERIEUX SA
  • GENMARK DIAGNOSTICS INC.
  • ALTONA DIAGNOSTICS
  • ELITECH GROUP
  • MAST GROUP LTD
  • KONINKLIJKE PHILIPS N.V.
  • SYSMEX CORPORATION
Product Code: 24117

Influenza Diagnostics Market Size And Forecast

Influenza Diagnostics Market size was valued at USD 0.84 Billion in 2024 and is projected to reach USD 1.56 Billion by 2031 , growing at a CAGR of 9.00% from 2024 to 2031. Influenza, commonly known as the flu, is an infection caused by the influenza virus. A variety of traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Reverse transcription-polymerase chain reaction and real-time molecular testing allows the detection of influenza genetic material. Continued advances in rapid influenza diagnostic testing have made this method effective for diagnosis due to its rapid results and ease of sample collection. Factors such as the increasing prevalence of influenza, increasing awareness of early detection using specific diagnostic tests, and a shift in focus from centralized laboratories to decentralized point-of-care testing are expected to drive the growth of the global influenza diagnostics market.

Additionally, due to the increasing prevalence of chronic diseases, the growing geriatric population, increasing government initiatives to monitor influenza, and the development of technologically advanced diagnostic tests for influenza, the demand for influenza diagnostics is likely to increase.

Emerging technologically advanced influenza diagnostic tests, including integration of point-of-care technology and influenza testing, are expected to facilitate the surveillance process in the geriatric population. In addition, point-of-care technology is expected to increase influenza testing in rural areas of the Asia-Pacific region, where access to health care is limited.

However, the cost of test and equipment development may hamper the market growth. Raw material availability and accessibility constraints increase the total cost of the product. The burden of high production costs is passed on to end users at high prices.

Global Influenza Diagnostics Market Dynamics

The key market dynamics that are shaping the global influenza diagnostics market include:

Key Market Drivers

Escalating Burden of Influenza:

Global seasonal influenza outbreaks cause significant sickness, hospitalizations, and deaths, emphasizing the need for rapid and precise diagnostic techniques. These tools are critical for making treatment decisions and carrying out effective management measures.

Increased Healthcare Awareness:

As the public becomes more aware of influenza and its repercussions, there is a greater demand for quick and simple diagnostic testing. This development represents a proactive attitude to health management, with people seeking easily accessible diagnostic solutions.

Advancements in Technology:

Novel technologies including as fast molecular assays, point-of-care tests, and multiplex assays are transforming influenza diagnostics. These advancements improve speed, accuracy, and the ability to identify many influenza strains at the same time, hence increasing diagnostic capabilities.

Emphasis on Early Detection and Treatment:

Early detection and treatment are crucial for early treatment and preventing complications from influenza. Rapid diagnostic tests allow for early intervention with antiviral drugs, which improves patient outcomes and reduces healthcare costs.

Expanding Geriatric Population

: As the world population ages, the elderly are especially vulnerable to influenza-related problems. This demographic transition highlights the importance of reliable and conveniently accessible diagnostic testing adapted to the demands of older persons.

Biothreat Preparedness:

Influenza viruses have the potential to cause pandemics, hence rapid and accurate diagnostic technologies are required for biothreat preparedness and response operations. Effective diagnostics are critical for limiting outbreaks and minimizing their damage.

Government Initiatives and Reimbursement Policies:

Several governments are launching public health initiatives to promote influenza vaccination and diagnosis. Furthermore, favorable payment rules for influenza diagnostic tests play an important role in increasing accessibility and encouraging widespread usage of these critical instruments.

Key Challenges:

Variability in Test Sensitivity and Specificity:

Inconsistencies in test performance, especially with quick testing, can lead to incorrect discrimination between influenza and other respiratory infections, resulting in misdiagnosis and poor treatment recommendations.

High Cost of Advanced Tests:

Advanced technologies such as molecular assays provide greater precision but come at a higher cost, limiting access, particularly in resource-constrained regions with restricted healthcare budgets.

Lack of Standardization:

The prevalence of several influenza diagnostic tests with differing performance characteristics complicates interpreting and comparing results across tests, causing uncertainty for healthcare practitioners and impeding effective patient treatment decisions.

Limited Availability in Remote Areas:

Access to advanced diagnostic tests is limited in distant or low-income areas, delaying diagnosis and treatment, especially for vulnerable groups that face barriers to accessing healthcare facilities with advanced testing capabilities.

Limited Skilled Personnel:

Certain modern influenza diagnostic tests necessitate specific training and skills to operate and interpret correctly. Even when these tests are available, a lack of competent workers in certain places prevents them from being used effectively.

Reimbursement Issues:

Inadequate reimbursement regulations for influenza diagnostics may prevent healthcare providers from adopting newer technologies, limiting overall market growth and the availability of improved tests.

False Positives and Negatives:

Despite improvements, some tests continue to provide false positive or negative results, resulting in wasteful treatments, resource waste, and patient worry, compromising the effectiveness and cost-efficiency of testing methodologies.

Evolving Viral Strains:

Influenza viruses are constantly changing, demanding ongoing updates and changes to diagnostic procedures in order to remain successful. The introduction of novel virus strains may result in increased expenditures and hurdles for diagnostic manufacturers in maintaining accurate and trustworthy diagnostic systems.

Key Trends:

Adoption of Rapid Diagnostic Tests:

Rapid influenza diagnostic tests (RIDTs) are becoming increasingly popular because to their convenience, speed, and ease of use, allowing for swift treatment decisions at the point of care.

Emergence of Multiplex Assays:

Multiplex assays are becoming popular because they may detect numerous respiratory infections, such as influenza viruses and RSV, in a single test, increasing efficiency and eliminating the need for multiple tests.

Focus on Point-of-Care Testing (POCT):

The industry is shifting toward developing point-of-care testing (POCT) solutions for influenza diagnostics, which will provide portable and user-friendly options for a variety of locations, including clinics, pharmacies, and homes.

Integration with Telehealth Platforms:

Influenza diagnostic tests are rapidly being connected with telehealth platforms, allowing for remote diagnosis and consultation, hence enhancing healthcare access, particularly in underprivileged areas.

Technological Advances in Molecular Diagnostics:

As technology advances, more sensitive and specific molecular assays for influenza diagnosis are being developed, allowing for differentiation between different influenza strains and aiding in targeted treatment strategies and vaccine development.

Integration of Artificial Intelligence:

Artificial intelligence (AI) algorithms are being integrated into influenza diagnostics to improve accuracy, identify new strains, and anticipate epidemics by using diagnostic test data analysis.

Growing Emphasis on Home-Based Testing:

The COVID-19 pandemic has increased demand for home-based diagnostic tests, and similar trends are projected for influenza diagnostics, as advances in user-friendly self-testing kits become more widely available.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Influenza Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global influenza diagnostics market:

North America

North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership.

The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

North America routinely devotes a high portion of its GDP to healthcare spending, allowing for major investment in healthcare technologies such as influenza diagnostics. The availability of large financial resources encourages the use of modern diagnostic tests and promotes market expansion in the region.

Each year, North America suffers significant seasonal influenza outbreaks, which cause a significant illness burden and public health impact. The incidence of influenza increases the demand for speedy and accurate diagnostic tests to guide treatment decisions, implement control measures, and limit disease spread, supporting the region's dominant position in the influenza diagnostics market.

Many of the world's largest influenza diagnostic firms, including those that make fast tests, molecular assays, and point-of-care devices, have their headquarters or a significant presence in North America. These companies use the region's superior infrastructure, research capabilities, and regulatory framework to develop and deliver breakthrough diagnostic solutions, reinforcing North America's market leadership.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the influenza diagnostics The Asia Pacific area is undergoing rapid economic expansion, which has coincided with advancements in healthcare infrastructure and access to medical services. Rising disposable incomes and government investments in healthcare drive up demand for diagnostic tests, especially those for influenza.

As Asia Pacific countries invest more in healthcare infrastructure and services, healthcare spending rises. This increasing investment promotes the use of innovative diagnostic technologies, hence driving growth in the influenza diagnostics market.

The Asia Pacific region's public is becoming more aware of infectious diseases, particularly influenza. Increased awareness generates more demand for diagnostic testing, particularly during influenza seasons, which contributes to market growth.

The Asia Pacific region has a vast and fast expanding population, especially in cities. Increased population density raises the risk of influenza transmission, driving up need for diagnostic tests to monitor and manage illness spread.

Countries in the Asia Pacific area are increasingly adopting innovative healthcare technologies, such as telemedicine platforms and point-of-care diagnostic devices. These technologies provide access to healthcare services and enable faster detection and treatment of influenza, resulting in market growth.

The COVID-19 pandemic has expedited the deployment of telehealth platforms throughout the Asia Pacific. The integration of influenza diagnostic tests with telehealth services allows for remote consultations and testing, increasing access to diagnostic services and driving market growth.

Global Influenza Diagnostics Market: Segmentation Analysis

The Global Influenza Diagnostics Market is segmented based on Product, End-User, Test Type, And Geography.

Influenza Diagnostics Market, By Product

  • Test kits and reagents.
  • Instruments
  • Others

Based on Product, the market is segmented into test kits and reagents, instruments, and others. Test kits and reagents dominate the Influenza Diagnostics Market, accounting for almost 60% of the total market share. This is due to a variety of causes, including its widespread availability through pharmacies, clinics, and internet sellers, frequently without the requirement for a prescription. These test kits are popular because they are simple to use; many are developed for point-of-care settings and require little training to administer. Furthermore, their low cost in comparison to other instruments makes them affordable to those with a variety of budgets. Given the importance of early influenza detection, these kits meet a significant need by offering a quick and accessible testing alternative. Furthermore, their versatility enables them to serve both healthcare professionals and those seeking self-testing choices at home.

Influenza Diagnostics Market, By End-User

  • Diagnostics laboratories
  • Hospitals & Clinic
  • Others

Based on End-users, the Global Influenza Diagnostics Market has been segmented into diagnostics laboratories, hospitals & clinics, and others. Hospitals and Clinics dominate the Influenza Diagnostics Market, owing to a number of important considerations. For starters, hospitals face a larger disease load, with a greater number of patients presenting with influenza-like symptoms, demanding frequent testing to ensure correct diagnosis and treatment decisions. Second, hospitals often have advanced testing capabilities, including access to a wide range of diagnostic tools and sophisticated apparatus, allowing for more precise and extensive testing procedures. Furthermore, hospitals have strong infrastructure and specialized people, such as dedicated laboratory facilities and trained experts who can successfully handle and interpret influenza diagnostic tests. Given the importance of prompt and correct diagnosis in patient treatment, hospitals prioritize diagnostic accuracy and efficiency. Furthermore, hospitals play an important role in public health surveillance by reporting influenza cases, relying on dependable diagnostic results to inform public health interventions and strategies.

Influenza Diagnostics Market, By Test Type

  • Traditional Test
  • Molecular Diagnostic Assay

Based on Test Type, the Global Influenza Diagnostics Market is classified into traditional tests and molecular diagnostic assay. While the Influenza Diagnostics Market is moving, traditional tests, such as Rapid Influenza Diagnostic Tests (RIDTs), continue to hold the majority share, accounting for around 66.7%. This is mostly due to various variables. First and foremost, traditional tests are less expensive than molecular assays, making them more accessible in a variety of healthcare settings. Furthermore, many traditional tests, particularly RIDTs, provide speedy results at the point of care, allowing for timely treatment options. Furthermore, their ease of use, with no administration training, makes them appropriate for widespread deployment in clinics and even self-testing. Given the high prevalence of influenza A and B, standard tests can detect the most common influenza strains, meeting a major amount of diagnostic needs. Moreover, the frequent use of traditional testing over a longer period has solidified their position in healthcare settings, contributing to their continued dominance in the market.

Influenza Diagnostics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Influenza Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables. North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership. The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

Key Players

  • The "Global Influenza Diagnostics Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
  • Abbott Laboratories, F. Hoffmann-La Roche Ltd. (Roche Diagnostics), Danaher Corporation (Beckton Dickinson), Abbott Laboratories (Alere), Siemens Healthineers AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD Diagnostics), Meril Diagnostics Pvt. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and QIAGEN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In May 2021, FDA approval has been received by Becton, Dickinson, and Company which is a medical technology company for the BD Veritor Plus System. The BD Veritor Plus System will play a vital role in detecting influenza A, influenza B, and SARS-CoV-2.
  • In March 2021, Emergency Use Authorization (EUA) was received from FDA for a laboratory PCR assay that will be beneficial in detecting and differentiating SARS-COV-2, RSV flu A, and flu B in a single test. It is manufactured by Abbott Laboratories which is a leading medical device and health care company.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.1 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET OVERVIEW
  • 3.2 GLOBAL INFLUENZA DIAGNOSTICS ABSOLUTE MARKET OPPORTUNITY
  • 3.3 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY REGION
  • 3.4 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY PRODUCT
  • 3.5 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY END-USER
  • 3.6 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY TEST TYPE
  • 3.7 GLOBAL INFLUENZA DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
  • 3.9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER (USD MILLION)
  • 3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION)
  • 3.11 FUTURE MARKET OPPORTUNITIES
  • 3.12 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET EVOLUTION
  • 4.2 GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
    • 4.3.1 GROWTH IN INFLUENZA RESEARCH FOR DIAGNOSTIC TECHNOLOGIES
    • 4.3.2 RISE IN PREVALENCE OF INFLUENZA
  • 4.4 RESTRAINTS
    • 4.4.1 UNSKILLED PROFESSIONALS
    • 4.4.2 STRINGENT FDA REGULATIONS
  • 4.5 OPPORTUNITIES
    • 4.5.1 ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES
    • 4.5.2 INCREASE IN THE NUMBER OF RESEARCH AND DEVELOPMENT ACTIVITIES
  • 4.6 IMPACT OF COVID-19 ON THE GLOBAL INFLUENZA DIAGNOSTICS MARKET
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 BARGAINING POWER OF BUYERS
    • 4.7.2 BARGAINING POWER OF SUPPLIERS
    • 4.7.3 THREAT OF SUBSTITUTES
    • 4.7.4 THREAT FROM NEW ENTRANTS
    • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 4.8 VALUE CHAIN ANALYSIS
  • 4.9 MACROECONOMIC ANALYSIS

5 MARKET, BY END-USER

  • 5.1 OVERVIEW
  • 5.1 DIAGNOSTIC LABORATORIES
  • 5.2 HOSPITALS AND CLINICS
  • 5.3 OTHERS

6 MARKET, BY PRODUCT

  • 6.1 OVERVIEW
  • 6.2 TEST KIT AND REAGENTS
  • 6.3 INSTRUMENTS
  • 6.4 OTHERS

7 MARKET, BY TEST TYPE

  • 7.1 OVERVIEW
  • 7.2 TRADITIONAL DIAGNOSTIC TEST
    • 7.2.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
    • 7.2.2 VIRAL CULTURE
    • 7.2.3 DIRECT FLUORESCENT ANTIBODY (DFA) TEST
    • 7.2.4 SEROLOGICAL ASSAY
  • 7.3 MOLECULAR DIAGNOSTIC ASSAY
    • 7.3.1 RT-PCR
    • 7.3.2 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TEST
    • 7.3.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
    • 7.3.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
    • 7.3.5 OTHER MOLECULAR DIAGNOSTIC ASSAYS

8 MARKET, BY GEOGRAPHY

  • 8.1 OVERVIEW
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
    • 8.2.2 U.S.
    • 8.2.3 CANADA
    • 8.2.4 MEXICO
  • 8.3 EUROPE
    • 8.3.1 EUROPE MARKET SNAPSHOT
    • 8.3.2 GERMANY
    • 8.3.3 U.K.
    • 8.3.4 FRANCE
    • 8.3.5 ITALY
    • 8.3.6 SPAIN
    • 8.3.7 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
    • 8.4.2 CHINA
    • 8.4.3 JAPAN
    • 8.4.4 INDIA
    • 8.4.5 REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
    • 8.5.2 BRAZIL
    • 8.5.3 ARGENTINA
    • 8.5.4 REST OF LATIN AMERICA
  • 8.6 MIDDLE EAST AND AFRICA
    • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
    • 8.6.2 UAE
    • 8.6.3 SAUDI ARABIA
    • 8.6.4 SOUTH AFRICA
    • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPETITIVE SCENARIO
  • 9.3 COMPANY MARKET RANKING ANALYSIS
  • 9.4 COMPANY REGIONAL FOOTPRINT
  • 9.5 COMPANY INDUSTRY FOOTPRINT
  • 9.6 ACE MATRIX
    • 9.6.1 ACTIVE
    • 9.6.2 CUTTING EDGE
    • 9.6.3 EMERGING
    • 9.6.4 INNOVATORS

10 COMPANY PROFILES

  • 10.1 ABBOTT LABORATORIES
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 COMPANY INSIGHTS
    • 10.1.3 SEGMENT BREAKDOWN
    • 10.1.4 PRODUCT BENCHMARKING
    • 10.1.5 KEY DEVELOPMENTS
    • 10.1.6 WINNING IMPERATIVES
    • 10.1.7 CURRENT FOCUS & STRATEGIES
    • 10.1.8 THREAT FROM COMPETITION
    • 10.1.9 SWOT ANALYSIS
  • 10.2 THERMO FISHER SCIENTIFIC INC.
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 COMPANY INSIGHTS
    • 10.2.3 SEGMENT BREAKDOWN
    • 10.2.4 PRODUCT BENCHMARKING
    • 10.2.5 KEY DEVELOPMENTS
    • 10.2.6 WINNING IMPERATIVES
    • 10.2.7 CURRENT FOCUS & STRATEGIES
    • 10.2.8 THREAT FROM COMPETITION
    • 10.2.9 SWOT ANALYSIS
  • 10.3 DANAHER CORPORATION
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 COMPANY INSIGHTS
    • 10.3.3 SEGMENT BREAKDOWN
    • 10.3.4 PRODUCT BENCHMARKING
    • 10.3.5 WINNING IMPERATIVES
    • 10.3.6 CURRENT FOCUS & STRATEGIES
    • 10.3.7 THREAT FROM COMPETITION
    • 10.3.8 SWOT ANALYSIS
  • 10.4 SIEMENS HEALTHINEERS AG
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 COMPANY INSIGHTS
    • 10.4.3 SEGMENT BREAKDOWN
    • 10.4.4 PRODUCT BENCHMARKING
    • 10.4.5 KEY DEVELOPMENTS
    • 10.4.6 WINNING IMPERATIVES
    • 10.4.7 CURRENT FOCUS & STRATEGIES
    • 10.4.8 THREAT FROM COMPETITION
    • 10.4.9 SWOT ANALYSIS
  • 10.5 HOFFMANN-LA ROCHE AG
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 COMPANY INSIGHTS
    • 10.5.3 SEGMENT BREAKDOWN
    • 10.5.4 PRODUCT BENCHMARKING
    • 10.5.5 KEY DEVELOPMENTS
    • 10.5.6 WINNING IMPERATIVES
    • 10.5.7 CURRENT FOCUS & STRATEGIES
    • 10.5.8 THREAT FROM COMPETITION
    • 10.5.9 SWOT ANALYSIS
  • 10.6 BECTON, DICKINSON, AND COMPANY
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 COMPANY INSIGHTS
    • 10.6.3 SEGMENT BREAKDOWN
    • 10.6.4 PRODUCT BENCHMARKING
    • 10.6.5 KEY DEVELOPMENTS
  • 10.7 DIASORIN & LUMINEX CORPORATION
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 COMPANY INSIGHTS
    • 10.7.3 SEGMENT BREAKDOWN
    • 10.7.4 PRODUCT BENCHMARKING
    • 10.7.5 KEY DEVELOPMENTS
    • 10.7.6 LUMINEX CORPORATION COMPANY OVERVIEW
    • 10.7.7 PRODUCT BENCHMARKING
  • 10.8 QUIDEL CORPORATION
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 COMPANY INSIGHTS
    • 10.8.3 SEGMENT BREAKDOWN
    • 10.8.4 PRODUCT BENCHMARKING
    • 10.8.5 KEY DEVELOPMENTS
  • 10.9 CORIS BIOCONCEPT
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 COMPANY INSIGHTS
    • 10.9.3 PRODUCT BENCHMARKING
  • 10.1 ANALYTIK JENA AG (ENDRESS+HAUSER AG)
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 COMPANY INSIGHTS
    • 10.10.3 SEGMENT BREAKDOWN
    • 10.10.4 PRODUCT BENCHMARKING
  • 10.11 MERIDIAN BIOSCIENCE
    • 10.11.1 COMPANY OVERVIEW
    • 10.11.2 COMPANY INSIGHTS
    • 10.11.3 SEGMENT BREAKDOWN
    • 10.11.4 PRODUCT BENCHMARKING
  • 10.12 SA SCIENTIFIC, LTD
    • 10.12.1 COMPANY OVERVIEW
    • 10.12.2 COMPANY INSIGHTS
    • 10.12.3 PRODUCT BENCHMARKING
  • 10.13 SEKISUI DIAGNOSTIC
    • 10.13.1 COMPANY OVERVIEW
    • 10.13.2 COMPANY INSIGHTS
    • 10.13.3 PRODUCT BENCHMARKING
    • 10.13.4 KEY DEVELOPMENTS
  • 10.14 HOLOGIC INC.
    • 10.14.1 COMPANY OVERVIEW
    • 10.14.2 COMPANY INSIGHTS
    • 10.14.3 SEGMENT BREAKDOWN
    • 10.14.4 PRODUCT BENCHMARKING
    • 10.14.5 KEY DEVELOPMENTS
  • 10.15 3M
    • 10.15.1 COMPANY OVERVIEW
    • 10.15.2 COMPANY INSIGHTS
    • 10.15.3 SEGMENT BREAKDOWN
    • 10.15.4 PRODUCT BENCHMARKING
  • 10.16 BIOMERIEUX SA
    • 10.16.1 COMPANY OVERVIEW
    • 10.16.2 COMPANY INSIGHTS
    • 10.16.3 SEGMENT BREAKDOWN
    • 10.16.4 PRODUCT BENCHMARKING
  • 10.17 GENMARK DIAGNOSTICS INC.
    • 10.17.1 COMPANY OVERVIEW
    • 10.17.2 COMPANY INSIGHTS
    • 10.17.3 PRODUCT BENCHMARKING
  • 10.18 ALTONA DIAGNOSTICS
    • 10.18.1 COMPANY OVERVIEW
    • 10.18.2 COMPANY INSIGHTS
    • 10.18.3 PRODUCT BENCHMARKING
    • 10.18.4 KEY DEVELOPMENT
  • 10.19 ELITECH GROUP
    • 10.19.1 COMPANY OVERVIEW
    • 10.19.2 COMPANY INSIGHTS
    • 10.19.3 PRODUCT BENCHMARKING
  • 10.2 MAST GROUP LTD
    • 10.20.1 COMPANY OVERVIEW
    • 10.20.2 COMPANY INSIGHTS
    • 10.20.3 PRODUCT BENCHMARKING
  • 10.21 KONINKLIJKE PHILIPS N.V.
    • 10.21.1 COMPANY OVERVIEW
    • 10.21.2 COMPANY INSIGHTS
    • 10.21.3 SEGMENT BREAKDOWN
    • 10.21.4 PRODUCT BENCHMARKING
  • 10.22 SYSMEX CORPORATION
    • 10.22.1 COMPANY OVERVIEW
    • 10.22.2 COMPANY INSIGHTS
    • 10.22.3 SEGMENT BREAKDOWN
    • 10.22.4 PRODUCT BENCHMARKING

LIST OF TABLES

  • TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 3 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 4 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 5 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY GEOGRAPHY, 2020-2030 (USD MILLION)
  • TABLE 6 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
  • TABLE 7 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 8 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 9 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 10 U.S. INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 11 U.S. INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 12 U.S. INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 13 CANADA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 14 CANADA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 15 CANADA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 16 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 17 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 18 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 19 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
  • TABLE 20 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 21 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 22 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 23 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 24 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 25 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 26 U.K. INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 27 U.K. INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 28 U.K. INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 29 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 30 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 31 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 32 ITALY INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 33 ITALY INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 34 ITALY INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 35 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 36 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 37 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 38 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 39 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 40 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
  • TABLE 42 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 45 CHINA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 46 CHINA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 47 CHINA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 48 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 49 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 50 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 51 INDIA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 52 INDIA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 53 INDIA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 54 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 55 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 56 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
  • TABLE 58 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 59 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 60 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 61 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 62 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 63 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 64 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 65 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 66 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 67 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 68 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 69 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 70 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
  • TABLE 71 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 72 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 73 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 74 UAE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 75 UAE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 76 UAE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 77 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 78 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 79 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 80 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 81 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 82 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 83 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
  • TABLE 84 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
  • TABLE 85 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
  • TABLE 86 COMPANY MARKET RANKING ANALYSIS
  • TABLE 87 COMPANY REGIONAL FOOTPRINT
  • TABLE 88 COMPANY INDUSTRY FOOTPRINT
  • TABLE 89 ABBOTT LABORATORIES: PRODUCT BENCHMARKING
  • TABLE 90 ABBOTT LABORATORIES: KEY DEVELOPMENTS
  • TABLE 91 ABBOTT LABORATORIES: WINNING IMPERATIVES
  • TABLE 92 THERMO FISHER SCIENTIFIC INC.: PRODUCT BENCHMARKING
  • TABLE 93 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
  • TABLE 94 THERMO FISHER SCIENTIFIC INC.: WINNING IMPERATIVES
  • TABLE 95 DANAHER CORPORATION: PRODUCT BENCHMARKING
  • TABLE 96 DANAHER CORPORATION: WINNING IMPERATIVES
  • TABLE 97 SIEMENS HEALTHINEERS AG: PRODUCT BENCHMARKING
  • TABLE 98 SIEMENS HEALTHINEERS AG: KEY DEVELOPMENTS
  • TABLE 99 SIEMENS HEALTHINEERS AG: WINNING IMPERATIVES
  • TABLE 100 HOFFMANN-LA ROCHE AG: PRODUCT BENCHMARKING
  • TABLE 101 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS
  • TABLE 102 HOFFMANN-LA ROCHE AG: WINNING IMPERATIVES
  • TABLE 103 BECTON, DICKINSON, AND COMPANY: PRODUCT BENCHMARKING
  • TABLE 104 BECTON, DICKINSON, AND COMPANY (BD): KEY DEVELOPMENTS
  • TABLE 105 DIASORIN: PRODUCT BENCHMARKING
  • TABLE 106 DIASORIN: KEY DEVELOPMENTS
  • TABLE 107 LUMINEX CORPORATION: PRODUCT BENCHMARKING
  • TABLE 108 QUIDEL CORPORATION: PRODUCT BENCHMARKING
  • TABLE 109 QUIDEL CORPORATION: KEY DEVELOPMENTS
  • TABLE 110 CORIS BIOCONCEPT: PRODUCT BENCHMARKING
  • TABLE 111 ANALYTIK JENA AG (ENDRESS+HAUSER AG): PRODUCT BENCHMARKING
  • TABLE 112 MERIDIAN BIOSCIENCS: PRODUCT BENCHMARKING
  • TABLE 113 SA SCIENTIFIC: PRODUCT BENCHMARKING
  • TABLE 114 SEKISUI DIAGNOSTICS: PRODUCT BENCHMARKING
  • TABLE 115 SEKISUI DIAGNOSTICS.: KEY DEVELOPMENTS
  • TABLE 116 HOLOGIC INC.: PRODUCT BENCHMARKING
  • TABLE 117 HOLOGIC INC.: KEY DEVELOPMENTS
  • TABLE 118 3M: PRODUCT BENCHMARKING
  • TABLE 119 BIOMERIEUX S. A.: PRODUCT BENCHMARKING
  • TABLE 120 GENMARK DIAGNOSTICS, INC..: PRODUCT BENCHMARKING
  • TABLE 121 ALTONA DIAGNOSTICS: PRODUCT BENCHMARKING
  • TABLE 122 ALTONA DIAGNOSTICS: KEY DEVELOPMENT
  • TABLE 123 ELITECH GROUP: PRODUCT BENCHMARKING
  • TABLE 124 MAST GROUP LTD: PRODUCT BENCHMARKING
  • TABLE 125 KONINKLIJKE PHILIPS N.V.: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 DATA SOURCES
  • FIGURE 6 GLOBAL INFLUENZA DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
  • FIGURE 7 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
  • FIGURE 8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER (USD MILLION)
  • FIGURE 9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION)
  • FIGURE 10 FUTURE MARKET OPPORTUNITIES
  • FIGURE 11 TRADITIONAL DIAGNOSTIC TEST SEGMENT DOMINATED THE MARKET IN 2021
  • FIGURE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
  • FIGURE 13 PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 14 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END-USER
  • FIGURE 15 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT
  • FIGURE 16 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE
  • FIGURE 17 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY GEOGRAPHY, 2020-2030 (USD MILLION)
  • FIGURE 18 U.S. MARKET SNAPSHOT
  • FIGURE 19 CANADA MARKET SNAPSHOT
  • FIGURE 20 MEXICO MARKET SNAPSHOT
  • FIGURE 21 GERMANY MARKET SNAPSHOT
  • FIGURE 22 U.K. MARKET SNAPSHOT
  • FIGURE 23 FRANCE MARKET SNAPSHOT
  • FIGURE 24 ITALY MARKET SNAPSHOT
  • FIGURE 25 SPAIN MARKET SNAPSHOT
  • FIGURE 26 REST OF EUROPE MARKET SNAPSHOT
  • FIGURE 27 CHINA MARKET SNAPSHOT
  • FIGURE 28 JAPAN MARKET SNAPSHOT
  • FIGURE 29 INDIA MARKET SNAPSHOT
  • FIGURE 30 REST OF ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 31 BRAZIL MARKET SNAPSHOT
  • FIGURE 32 ARGENTINA MARKET SNAPSHOT
  • FIGURE 33 REST OF LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 34 UAE MARKET SNAPSHOT
  • FIGURE 35 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 36 SOUTH AFRICA MARKET SNAPSHOT
  • FIGURE 37 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 38 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 39 ACE MATRIC
  • FIGURE 40 ABBOTT LABORATORIES: COMPANY INSIGHT
  • FIGURE 41 ABBOTT LABORATORIES: BREAKDOWN
  • FIGURE 42 ABBOTT LABORATORIES: SWOT ANALYSIS
  • FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY INSIGHT
  • FIGURE 44 THERMO FISHER SCIENTIFIC INC.: BREAKDOWN
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
  • FIGURE 46 DANAHER CORPORATION: COMPANY INSIGHT
  • FIGURE 47 DANAHER CORPORATION: BREAKDOWN
  • FIGURE 48 DANAHER CORPORATION: SWOT ANALYSIS
  • FIGURE 49 SIEMENS HEALTHINEERS AG.: COMPANY INSIGHT
  • FIGURE 50 SIEMENS HEALTHINEERS AG: SEGMENT BREAKDOWN
  • FIGURE 51 SIEMENS HEALTHINEERS AG: SWOT ANALYSIS
  • FIGURE 52 HOFFMANN-LA ROCHE AG: COMPANY INSIGHT
  • FIGURE 53 HOFFMANN-LA ROCHE AG: BREAKDOWN
  • FIGURE 54 HOFFMANN-LA ROCHE AG: SWOT ANALYSIS
  • FIGURE 55 BECTON, DICKINSON, AND COMPANY: COMPANY INSIGHT
  • FIGURE 56 BECTON, DICKINSON, AND COMPANY: BREAKDOWN
  • FIGURE 57 DIASORIN & LUMINEX CORPORATION: COMPANY INSIGHT
  • FIGURE 58 DIASORIN & LUMINEX CORPORATION: BREAKDOWN
  • FIGURE 59 QUIDEL CORPORATION: COMPANY INSIGHT
  • FIGURE 60 QUIDEL CORPORATION: BREAKDOWN
  • FIGURE 61 CORIS BIOCONCEPT: COMPANY INSIGHT
  • FIGURE 62 ANALYTIK JENA AG (ENDRESS+HAUSER AG): COMPANY INSIGHT
  • FIGURE 63 ANALYTIK JENA AG (ENDRESS+HAUSER AG): BREAKDOWN
  • FIGURE 64 MERIDIAN BIOSCIENCES: COMPANY INSIGHT
  • FIGURE 65 MERIDIAN BIOSCIENCES: BREAKDOWN
  • FIGURE 66 SA SCIENTIFIC: COMPANY INSIGHT
  • FIGURE 67 SEKISUI DIAGNOSTIC: COMPANY INSIGHT
  • FIGURE 68 HOLOGIC INC: COMPANY INSIGHT
  • FIGURE 69 HOLOGIC INC: SEGMENT BREAKDOWN
  • FIGURE 70 3M.: COMPANY INSIGHT
  • FIGURE 71 3M: SEGMENT BREAKDOWN
  • FIGURE 72 BIOMERIEUX S. A.: COMPANY INSIGHT
  • FIGURE 73 BIOMERIEUX S. A.: BREAKDOWN
  • FIGURE 74 GENMARK DIAGNOSTICS INC.: COMPANY INSIGHT
  • FIGURE 75 ALTONA DIAGNOSTICS.: COMPANY INSIGHT
  • FIGURE 76 ELITECH GROUP: COMPANY INSIGHT
  • FIGURE 77 MAST GROUP LTD: COMPANY INSIGHT
  • FIGURE 78 KONINKLIJKE PHILIPS N.V: COMPANY INSIGHT
  • FIGURE 79 KONINKLIJKE PHILIPS N.V: SEGMENT BREAKDOWN
  • FIGURE 80 SYSMEX CORPORATION.: COMPANY INSIGHT
  • FIGURE 81 SYSMEX CORPORATION.: SEGMENT BREAKDOWN